Logo image of GELS

GELTEQ LTD (GELS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GELS - AU0000218109 - Common Stock

1.04 USD
-0.2 (-16.13%)
Last: 1/16/2026, 8:22:36 PM
1.05 USD
+0.01 (+0.96%)
After Hours: 1/16/2026, 8:22:36 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to GELS. GELS was compared to 191 industry peers in the Pharmaceuticals industry. GELS may be in some trouble as it scores bad on both profitability and health. GELS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year GELS has reported negative net income.
  • GELS had a negative operating cash flow in the past year.
  • GELS had negative earnings in each of the past 5 years.
  • GELS had a negative operating cash flow in each of the past 5 years.
GELS Yearly Net Income VS EBIT VS OCF VS FCFGELS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -2M -4M -6M

1.2 Ratios

  • GELS has a Return On Assets (-30.94%) which is in line with its industry peers.
  • GELS has a Return On Equity (-42.05%) which is in line with its industry peers.
Industry RankSector Rank
ROA -30.94%
ROE -42.05%
ROIC N/A
ROA(3y)-21.21%
ROA(5y)-16.14%
ROE(3y)-28.1%
ROE(5y)-20.64%
ROIC(3y)N/A
ROIC(5y)N/A
GELS Yearly ROA, ROE, ROICGELS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 -10 -20 -30 -40

1.3 Margins

  • Looking at the Gross Margin, with a value of 30.36%, GELS is in line with its industry, outperforming 57.29% of the companies in the same industry.
  • GELS's Gross Margin has declined in the last couple of years.
  • GELS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.29%
GM growth 5YN/A
GELS Yearly Profit, Operating, Gross MarginsGELS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

  • GELS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • GELS has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for GELS is higher compared to a year ago.
GELS Yearly Shares OutstandingGELS Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
GELS Yearly Total Debt VS Total AssetsGELS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • GELS has an Altman-Z score of -0.42. This is a bad value and indicates that GELS is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.42, GELS is in line with its industry, outperforming 43.23% of the companies in the same industry.
  • GELS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • GELS has a better Debt to Equity ratio (0.00) than 61.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.42
ROIC/WACCN/A
WACC8.32%
GELS Yearly LT Debt VS Equity VS FCFGELS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 5M -5M 10M 15M 20M

2.3 Liquidity

  • A Current Ratio of 0.27 indicates that GELS may have some problems paying its short term obligations.
  • With a Current ratio value of 0.27, GELS is not doing good in the industry: 94.27% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.27 indicates that GELS may have some problems paying its short term obligations.
  • The Quick ratio of GELS (0.27) is worse than 92.71% of its industry peers.
Industry RankSector Rank
Current Ratio 0.27
Quick Ratio 0.27
GELS Yearly Current Assets VS Current LiabilitesGELS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for GELS have decreased strongly by -87.41% in the last year.
  • Measured over the past years, GELS shows a small growth in Revenue. The Revenue has been growing by 3.95% on average per year.
EPS 1Y (TTM)-87.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-486.26%
Revenue 1Y (TTM)N/A
Revenue growth 3Y3.95%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GELS Yearly Revenue VS EstimatesGELS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2025 50K 100K 150K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GELS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GELS Price Earnings VS Forward Price EarningsGELS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GELS Per share dataGELS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for GELS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GELTEQ LTD

NASDAQ:GELS (1/16/2026, 8:22:36 PM)

After market: 1.05 +0.01 (+0.96%)

1.04

-0.2 (-16.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-17
Earnings (Next)06-22
Inst Owners0.88%
Inst Owner ChangeN/A
Ins Owners41.53%
Ins Owner ChangeN/A
Market Cap11.14M
Revenue(TTM)165.70K
Net Income(TTM)-6.65M
AnalystsN/A
Price TargetN/A
Short Float %0.72%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 100.36
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.01
BVpS0.99
TBVpS-0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.94%
ROE -42.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.36%
FCFM N/A
ROA(3y)-21.21%
ROA(5y)-16.14%
ROE(3y)-28.1%
ROE(5y)-20.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.29%
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 387.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.27
Quick Ratio 0.27
Altman-Z -0.42
F-Score4
WACC8.32%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-486.26%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y3.95%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-94.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-405.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-415.8%
OCF growth 3YN/A
OCF growth 5YN/A

GELTEQ LTD / GELS FAQ

Can you provide the ChartMill fundamental rating for GELTEQ LTD?

ChartMill assigns a fundamental rating of 1 / 10 to GELS.


What is the valuation status of GELTEQ LTD (GELS) stock?

ChartMill assigns a valuation rating of 0 / 10 to GELTEQ LTD (GELS). This can be considered as Overvalued.


Can you provide the profitability details for GELTEQ LTD?

GELTEQ LTD (GELS) has a profitability rating of 1 / 10.


Can you provide the financial health for GELS stock?

The financial health rating of GELTEQ LTD (GELS) is 1 / 10.